<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230130057273N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-12-17</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of transversus abdominis nerve block with rectus sheath nerve block in pain control after laparoscopic cholecystectomy in patients of Imam Khomeini Hospital Complex, 2026</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of transversus abdominis nerve block with rectus sheath nerve block in pain control after laparoscopic cholecystectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/87909</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this randomized clinical trial, eligible patients will be allocated after confirmation of the inclusion/exclusion criteria and obtaining written informed consent. Participants will be assigned using simple randomization with a 1:1 allocation ratio to one of the following two groups: the TAP block group (transversus abdominis plane block) and the rectus sheath block group.
1) Randomization method
Type of randomization: Simple randomization (without blocking and without stratification). For each participant, an independent random assignment will be generated and allocated to one of two groups (A/B). Quasi-random methods (e.g., alternating assignment, date of birth, medical record number, day of visit, etc.) will not be used.
2) Unit of randomization
Unit: Individual randomization; each patient constitutes an independent unit for allocation. Cluster or multilevel randomization will not be performed in this study.
3) Stratification
Stratified randomization will not be used. All eligible participants will enter the randomization process without stratification.
4) Randomization tools
Random sequence generation tool: Computer-generated random numbers using SPSS.
Allocation implementation at the bedside: Sequentially numbered, opaque, sealed envelopes (SNOSE).
5) Generation of the random sequence
The allocation sequence will be generated by an individual independent of the clinical implementation team. A list of assignments with a length equal to the required sample size will be created, and for each entry, allocation to A or B will be generated with equal probability (0.5/0.5). The final output will be a serial list in which each sequential number corresponds to a specific allocation (A/B).
6) Allocation concealment
 To minimize selection bias, allocation concealment will be ensured using the SNOSE method. Envelopes will be opaque, light-impermeable, sealed, and sequentially numbered. Each envelope will contain a card indicating the group code (A = TAP, B = Rectus Sheath). Envelopes will be prepared by an independent person and stored securely. The envelope will be opened only after final confirmation of patient eligibility and documentation of written informed consent, Blinding description: To minimize bias, participants, postoperative care staff, data collectors, and outcome assessors will be blinded to group allocation. The blocks will be performed after induction of general anesthesia, and identical dressings will be applied over the injection sites. Group allocation will be implemented using sequentially numbered, opaque, sealed envelopes (SNOSE) and will be disclosed only to the anesthesiologist performing the block; in documents accessible to outcome assessors, allocation will be recorded only as code A/B. The postoperative pain management protocol will be identical and pre-standardized in both groups. Statistical analyses will be conducted using coded groups, and unblinding will take place only after database lock.</study_design>
      <phase>3</phase>
      <hc_freetext>Acute pain occurring in the early postoperative period after elective laparoscopic cholecystectomy, requiring postoperative analgesia..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After induction of general anesthesia and before surgical incision, participants receive an ultrasound guided transversus abdominis plane block. A total of 20 millilitres of bupivacaine 0.25 percent is injected into the appropriate plane. All other anesthesia components and the postoperative pain management protocol are standardized according to the study protocol. Intervention 2: Intervention group: After induction of general anesthesia and before surgical incision, participants receive an ultrasound guided rectus sheath block. A total of 20 millilitres of bupivacaine 0.25 percent is injected into the rectus sheath plane. All other anesthesia components and the postoperative pain management protocol are standardized according to the study protocol.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Babak Eslami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Baqerkhan Ave, Chamran Highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 21 6119 0000</telephone>
        <email>beslami@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Babak Eslami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Baqerkhan Ave, Chamran Highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 21 6119 0000</telephone>
        <email>beslami@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>ASA class I &amp; II
Informed consent to participate in the project
BMI between 18 and 35</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to anesthetic drugs used in the plan
failure of the chosen method
Patient's unwillingness to participate in the plan
Localized sepsis at the site of the block
Alcohol or drug abuse
History of any coagulation disorder
Surgery time more than 3 hours
Surgeries in which the patient experiences surgical complications during the operation for any reason
Any mental or psychological disorder
History of serious painful illness</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pain, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After induction of general anesthesia and before surgical incision, participants receive an ultrasound guided transversus abdominis plane block. A total of 20 millilitres of bupivacaine 0.25 percent is injected into the appropriate plane. All other anesthesia components and the postoperative pain management protocol are standardized according to the study protocol.</i_keyword>
      <i_keyword>Intervention group: After induction of general anesthesia and before surgical incision, participants receive an ultrasound guided rectus sheath block. A total of 20 millilitres of bupivacaine 0.25 percent is injected into the rectus sheath plane. All other anesthesia components and the postoperative pain management protocol are standardized according to the study protocol.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postoperative pain intensity at rest. Timepoint: 2, 6, 12, and 24 hours after surgery. Method of measurement: Visual analogue scale, a 10 centimetre line anchored by no pain and worst imaginable pain.</prim_outcome>
      <prim_outcome>Cumulative intravenous morphine dose administered during the first 24 hours after surgery. Timepoint: From the end of surgery to 24 hours after surgery. Method of measurement: Total intravenous morphine dose extracted from the medication administration record and patient chart.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Total intravenous fentanyl dose administered intraoperatively. Timepoint: At the end of surgery, as the cumulative dose from induction of anesthesia to the end of surgery. Method of measurement: Total intravenous fentanyl dose extracted from the anesthesia record and intraoperative medication chart.</sec_outcome>
      <sec_outcome>Need for intravenous ketorolac administration in the post anesthesia care unit. Timepoint: During the post anesthesia care unit stay, from admission to discharge. Method of measurement: Documentation of intravenous ketorolac administration in the post anesthesia care unit medication administration record.</sec_outcome>
      <sec_outcome>Incidence of block related complications. Timepoint: During block performance and up to 24 hours after surgery. Method of measurement: Clinical assessment and documentation of adverse events including injection site hematoma or bleeding, signs of local infection, signs of local anesthetic systemic toxicity, and any other reported adverse events.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-09-30</approval_date>
        <contact_name>Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Keshavarz Blvd., Central Building of Tehran University of Medical Sciences Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
